• linkedin
  • Increase Font
  • Sharebar

    10 More Newly Approved Drugs

    The FDA is having a productive 2017.



    INGREZZA (valbenazine), Neurocrine 

    Indications: A vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

    Dosage: Initial dose is 40 mg once daily, after one week, increase the dose to the recommended dose of 80 mg once daily. Can be taken with or without food. The recommended dose for patients with moderate or severe hepatic impairment is 40 mg once daily. Consider dose reduction based on tolerability in known CYP2D6 poor metabolizers.

    Contraindications: None.

    Read the prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available